Sydney Jennings

Your daily dose of the clinical news you may have missed.

Gepotidacin becomes the first new oral antibiotic for gonorrhea in over 30 years, offering hope for effective treatment options.

Two global phase 3 trials found rocatinlimab significantly improved EASI-75 and vIGA-AD outcomes at 24 weeks in people with moderate-to-severe AD with acceptable safety.

Your daily dose of the clinical news you may have missed.

Intranasal epinephrine emerges as a safe, effective alternative for anaphylaxis treatment, offering ease of use and promising real-world results.

Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.

A cohort study of 531 851 primary care patients found routine AUDIT-C alcohol screening scores predict 8-year all-cause mortality, with strongest effects in younger adults.

Your daily dose of the clinical news you may have missed.

A new rapid HIV test accurately differentiates vaccine-induced false positives from active HIV-1 infection, potentially improving diagnostics and vaccine trials.

A new meta-analysis reveals monoclonal antibodies, including dupilumab, outperform placebo in treating moderate-to-severe atopic dermatitis.

Your daily dose of the clinical news you may have missed.

A multinational survey of HS specialists in Europe found that 81% prescribe antibiotics despite expecting poor response and 79% favor earlier biologic initiation.

Your daily dose of the clinical news you may have missed.

Topical roflumilast 0.3% improved IGA, PASI, itch, and symptom scores in plaque psoriasis with a safety profile comparable to vehicle.

Highlights include widespread lack of structured menopause education in primary care residency programs, sleep benefits of elinzanetant, and more.

CTAD 2025: Early, continued treatment with lecanemab may delay Alzheimer disease progression by up to 8.3 years; SC dosing demonstrates bioequivalence.

The updated guideline from the American Cancer Society introduces self-collection for HPV testing and new exit criteria to enhance accessibility.

Insulet enhances the Omnipod® 5 system with new glucose targets and algorithms, improving insulin delivery for diabetes management.

Discover key insights from the latest Weekly Dose Podcast, covering cognitive health, reproductive care, and Alzheimer diagnostics for primary care clinicians.

Your daily dose of the clinical news you may have missed.

New data reveals lecanemab's significant impact on amyloid-beta protofibrils in Alzheimer disease, showcasing its potential to slow disease progression.

Your daily dose of the clinical news you may have missed.

Lisa Larkin, MD, explains how new therapies like elinzanetant reflect a major shift in menopause care and rising demand for better clinician education.

New findings reveal etalanetug significantly reduces tau biomarkers in Alzheimer’s patients, paving the way for innovative blood-based assessments of tau pathology.

New data reveals evolocumab significantly reduces long-term major cardiovascular event risks in ASCVD patients, enhancing treatment strategies for better outcomes.

Your daily dose of the clinical news you may have missed.

Mental health apps show high initial uptake but moderate adherence, revealing key factors for improving user retention in clinical trials.

Novo Nordisk submits an FDA application for semaglutide 7.2 mg for chronic weight management, supported by STEP UP trial data showing greater weight loss.

Your daily dose of the clinical news you may have missed.

Otsuka seeks FDA approval for centanafadine, a novel ADHD treatment showing significant efficacy and safety in pivotal trials for all age groups.